A new paediatric formulation of valaciclovir

development and bioequivalence assessment

Diane E T Bastiaans, Carli M Bartels-Wilmer, Angela P H Colbers, Claudia A W Heijens, Kirsten Velthoven-Graafland, Oscar S N M Smeets, Nicole Vink, Veroniek E M Harbers, Adilia Warris, David M Burger

Research output: Contribution to journalLetter

1 Citation (Scopus)
5 Downloads (Pure)

Abstract

A paediatric formulation of valaciclovir with acceptable palatability, good pharmaceutical quality and stability, and with the possibility of flexible dosing is currently not available. A preparation of valaciclovir liquid using crushed tablets as described in the US Food and Drug Administration label information was found not to be adequate for use in daily practice.1 The mean relative bioavailability of this liquid compared with the tablets was reported to be 91.1% (SD, 33.1%), but was not investigated following the regulatory guidance for bioequivalence testing.2 Aim of this study was to develop a new paediatric formulation and to assess the bioequivalence of this new formulation compared with the brand named valaciclovir tablets.

An oral liquid was developed because this is generally considered acceptable for use in infants and young children.3 Dosing accuracy, use of non-toxic excipients, palatability and good pharmaceutical stability for an acceptable period of time were taken into account during development.
Original languageEnglish
Pages (from-to)971-972
Number of pages2
JournalArchives of Disease in Childhood
Volume101
Issue number10
Early online date9 May 2016
DOIs
Publication statusPublished - Oct 2016

Fingerprint

valacyclovir
Therapeutic Equivalency
Tablets
Pediatrics
Excipients
United States Food and Drug Administration
Pharmaceutical Preparations
Biological Availability

Cite this

Bastiaans, D. E. T., Bartels-Wilmer, C. M., Colbers, A. P. H., Heijens, C. A. W., Velthoven-Graafland, K., Smeets, O. S. N. M., ... Burger, D. M. (2016). A new paediatric formulation of valaciclovir: development and bioequivalence assessment. Archives of Disease in Childhood, 101(10), 971-972. https://doi.org/10.1136/archdischild-2015-310266

A new paediatric formulation of valaciclovir : development and bioequivalence assessment. / Bastiaans, Diane E T; Bartels-Wilmer, Carli M; Colbers, Angela P H; Heijens, Claudia A W; Velthoven-Graafland, Kirsten; Smeets, Oscar S N M; Vink, Nicole; Harbers, Veroniek E M; Warris, Adilia; Burger, David M.

In: Archives of Disease in Childhood, Vol. 101, No. 10, 10.2016, p. 971-972.

Research output: Contribution to journalLetter

Bastiaans, DET, Bartels-Wilmer, CM, Colbers, APH, Heijens, CAW, Velthoven-Graafland, K, Smeets, OSNM, Vink, N, Harbers, VEM, Warris, A & Burger, DM 2016, 'A new paediatric formulation of valaciclovir: development and bioequivalence assessment', Archives of Disease in Childhood, vol. 101, no. 10, pp. 971-972. https://doi.org/10.1136/archdischild-2015-310266
Bastiaans DET, Bartels-Wilmer CM, Colbers APH, Heijens CAW, Velthoven-Graafland K, Smeets OSNM et al. A new paediatric formulation of valaciclovir: development and bioequivalence assessment. Archives of Disease in Childhood. 2016 Oct;101(10):971-972. https://doi.org/10.1136/archdischild-2015-310266
Bastiaans, Diane E T ; Bartels-Wilmer, Carli M ; Colbers, Angela P H ; Heijens, Claudia A W ; Velthoven-Graafland, Kirsten ; Smeets, Oscar S N M ; Vink, Nicole ; Harbers, Veroniek E M ; Warris, Adilia ; Burger, David M. / A new paediatric formulation of valaciclovir : development and bioequivalence assessment. In: Archives of Disease in Childhood. 2016 ; Vol. 101, No. 10. pp. 971-972.
@article{1afef630631248e0867278067ebdd4a6,
title = "A new paediatric formulation of valaciclovir: development and bioequivalence assessment",
abstract = "A paediatric formulation of valaciclovir with acceptable palatability, good pharmaceutical quality and stability, and with the possibility of flexible dosing is currently not available. A preparation of valaciclovir liquid using crushed tablets as described in the US Food and Drug Administration label information was found not to be adequate for use in daily practice.1 The mean relative bioavailability of this liquid compared with the tablets was reported to be 91.1{\%} (SD, 33.1{\%}), but was not investigated following the regulatory guidance for bioequivalence testing.2 Aim of this study was to develop a new paediatric formulation and to assess the bioequivalence of this new formulation compared with the brand named valaciclovir tablets.An oral liquid was developed because this is generally considered acceptable for use in infants and young children.3 Dosing accuracy, use of non-toxic excipients, palatability and good pharmaceutical stability for an acceptable period of time were taken into account during development.",
author = "Bastiaans, {Diane E T} and Bartels-Wilmer, {Carli M} and Colbers, {Angela P H} and Heijens, {Claudia A W} and Kirsten Velthoven-Graafland and Smeets, {Oscar S N M} and Nicole Vink and Harbers, {Veroniek E M} and Adilia Warris and Burger, {David M}",
year = "2016",
month = "10",
doi = "10.1136/archdischild-2015-310266",
language = "English",
volume = "101",
pages = "971--972",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "10",

}

TY - JOUR

T1 - A new paediatric formulation of valaciclovir

T2 - development and bioequivalence assessment

AU - Bastiaans, Diane E T

AU - Bartels-Wilmer, Carli M

AU - Colbers, Angela P H

AU - Heijens, Claudia A W

AU - Velthoven-Graafland, Kirsten

AU - Smeets, Oscar S N M

AU - Vink, Nicole

AU - Harbers, Veroniek E M

AU - Warris, Adilia

AU - Burger, David M

PY - 2016/10

Y1 - 2016/10

N2 - A paediatric formulation of valaciclovir with acceptable palatability, good pharmaceutical quality and stability, and with the possibility of flexible dosing is currently not available. A preparation of valaciclovir liquid using crushed tablets as described in the US Food and Drug Administration label information was found not to be adequate for use in daily practice.1 The mean relative bioavailability of this liquid compared with the tablets was reported to be 91.1% (SD, 33.1%), but was not investigated following the regulatory guidance for bioequivalence testing.2 Aim of this study was to develop a new paediatric formulation and to assess the bioequivalence of this new formulation compared with the brand named valaciclovir tablets.An oral liquid was developed because this is generally considered acceptable for use in infants and young children.3 Dosing accuracy, use of non-toxic excipients, palatability and good pharmaceutical stability for an acceptable period of time were taken into account during development.

AB - A paediatric formulation of valaciclovir with acceptable palatability, good pharmaceutical quality and stability, and with the possibility of flexible dosing is currently not available. A preparation of valaciclovir liquid using crushed tablets as described in the US Food and Drug Administration label information was found not to be adequate for use in daily practice.1 The mean relative bioavailability of this liquid compared with the tablets was reported to be 91.1% (SD, 33.1%), but was not investigated following the regulatory guidance for bioequivalence testing.2 Aim of this study was to develop a new paediatric formulation and to assess the bioequivalence of this new formulation compared with the brand named valaciclovir tablets.An oral liquid was developed because this is generally considered acceptable for use in infants and young children.3 Dosing accuracy, use of non-toxic excipients, palatability and good pharmaceutical stability for an acceptable period of time were taken into account during development.

U2 - 10.1136/archdischild-2015-310266

DO - 10.1136/archdischild-2015-310266

M3 - Letter

VL - 101

SP - 971

EP - 972

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 10

ER -